Navigation Links
Melanoma vaccine strategy shows promise in laboratory experiments

A novel approach to creating a vaccine to treat melanoma has demonstrated promising effectiveness in a new laboratory study led by researchers at The Wistar Institute. About a third of melanoma patients might benefit from such a vaccine. The study appears in the current issue of Cancer Research.

In the study, the scientists used a small protein called a peptide found in approximately 70 percent of melanomas, but not in normal cells, to stimulate immune cells called killer T cells to attack the melanoma cells. Another type of immune cell called a monocyte was used to present the peptide, BRAFV600E, to the killer T cells to trigger their attack on the melanoma cells.

"In our experiments, we saw a strong cancer-killing immune response when killer T cells are stimulated with this peptide," says Dorothee Herlyn, D.V.M., senior author on the study and a professor in the Immunology Program and Molecular and Cellular Oncogenesis Program at Wistar. "The results emphasize the potential of this approach for creating an effective melanoma vaccine, and we hope to move toward human clinical trials as soon as possible."

A substantial proportion of melanoma patients, about 50 percent, have killer T cells able to recognize the BRAFV600E peptide. Combining the prevalence of the peptide among melanoma patients ?about 70 percent ?with the number of patients whose immune cells are able to respond to the peptide suggests that a vaccine based on BRAFV600E could treat approximately a third of all melanoma patients.

Herlyn adds that the specificity of the peptide ?the fact that it is found only in melanoma cells, not normal cells ?suggests that the toxicity of any vaccine based on the peptide would be minimal. Killer T cells sparked into action by the vaccine would target only the cancer cells, sparing healthy cells entirely.

Looking ahead to possible human clinical trials, another member of the scientific team, University of Pennsylvania assistant pro fessor Brian Czerniecki, M.D., Ph.D., is working to prepare yet another type of immune cell, called a dendritic cell, to present the BRAFV600E peptide to killer T cells. Dendritic cells have as their primary job the presentation of foreign materials to the immune system, and the expectation is that dendritic cells presenting the BRAFV600E peptide would trigger the killer T cells even more effectively than the monocyte cells used in the current study. Indeed, such prepared dendritic cells might serve as the basis for a treatment vaccine that could be taken into human clinical trials.

Herlyn is senior author on the Cancer Research study. The lead author is Rajasekharan Somasundaram, also at Wistar. The additional Wistar coauthors are Rolf Swoboda, Laura Caputo, and Laszlo Otvos (now at Temple University). The remaining coauthors are Barbara Weber, Patricia Volpe, Patricia van Belle, Susan Hotz, David E. Elder, Lynn Schuchter, DuPont Guerry, and Brian J. Czerniecki of the University of Pennsylvania, and Francesco M. Marincola with the National Institutes of Health.


'"/>

Source:The Wistar Institute


Related biology news :

1. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
2. Research advances quest for HIV-1 vaccine
3. A much-needed shot in the arm for HIV vaccine development
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. Gene vaccine for Alzheimers disease shows promising results
6. Influenza vaccine uses insect cells to speed development
7. Norovirus, AIDS vaccine and Hepatitis Virus
8. HIV vaccine trial breaks ground for future research
9. Live vaccines more effective against horse herpes virus
10. NIAID begins clinical trial of West Nile virus vaccine
11. Designing vaccines by computer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... Despite the volatility that continues to ... Today,s pre-market research on ActiveWallSt.com directs the investor community,s focus ... RDUS ), Cerus Corp. (NASDAQ: CERS ), ... Prime Therapeutics Inc. (NASDAQ: FPRX ). Register with ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
Breaking Biology Technology: